View Clinical Trial (Medical Research Study)
Eszopiclone in the Treatment of Insomnia and Fibromyalgia - NCT00392041-08854(Clinical Trial 153971)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Piscataway |
|
State:
|
|
NJ |
| Zip Code: |
|
08854 |
| Conditions: |
|
Fibromyalgia - Insomnia |
| Purpose: |
|
The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other
symptoms of fibromyalgia. It is hypothesized that participants receiving eszopiclone will
report greater improvement in total sleep time, sleep quality, pain, fatigue, physical
functioning, and emotional distress than will those receiving placebo.
|
| Study summary: |
|
Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the
pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature
of most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia,
but has not been studied in the treatment of FMS. The purpose is to assess the efficacy of
eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia (FMS) in FMS
patients. Participants will be randomly selected to receive eszopiclone or placebo. It is
hypothesized that participants receiving eszopiclone will report greater improvement in
total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress
than will those receiving placebo. |
| Criteria: |
|
Inclusion Criteria:
1. Male or female, age 18 through 64.
2. Meets ACR criteria for FMS, as determined by rheumatological examination and a
medical history review.
3. Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep
impairment consisting of 3 of 7 nights per week for a month by history) or sleep
onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as
well as clinically significant daytime distress or impairment during the 1 week self
assessment prior to baseline.
4. Has completed 8th grade and is fluent in English.
5. If a female of child bearing potential, the patient must be non-pregnant and either
post-menopausal or using an approved birth control method. Acceptable birth control
methods include: history of tubal ligation, having a male partner who is sterile,
IUDs, birth control pills or other hormonal birth control methods (e.g., birth
control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and
foam).
6. Antidepressant medication will be allowed if the patient has been on a stable dose
for at least one month.
Exclusion Criteria:
1. Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or
endocrine-related arthropathy.
2. Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing
(central or obstructive apnea), periodic limb movement disorder, or REM sleep
behavior disorder.
3. Any current, clinically significant medical condition.
4. Pregnancy.
5. Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain
syndrome, or psychoactive substance abuse or dependence.
6. Any current psychiatric disorder that would interfere with study participation
(investigator judgment).
7. Active suicidal ideation.
8. Plans to engage in additional psychotherapy during the study.
9. Concurrent use of benzodiazepines after 6pm or as a sleep aid.
10. Concurrent use of any other sleep aid.
11. Concurrent use of analgesics other than acetaminophen or non-steroidal
anti-inflammatory medication.
12. Concurrent use of any medication that has not been stabilized for at least 1 month
prior to screening. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 1, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|